Cargando…

Autologous Immune Cell-Based Regenerative Therapies to Treat Vasculogenic Erectile Dysfunction: Is the Immuno-Centric Revolution Ready for the Prime Time?

About 35% of patients affected by erectile dysfunction (ED) do not respond to oral phosphodiesterase-5 inhibitors (PDE5i) and more severe vasculogenic refractory ED affects diabetic patients. Innovative approaches, such as regenerative therapies, including stem cell therapy (SCT) and platelet-rich p...

Descripción completa

Detalles Bibliográficos
Autores principales: Bonanni, Michela, Rehak, Laura, Massaro, Gianluca, Benedetto, Daniela, Matteucci, Andrea, Russo, Giulio, Esperto, Francesco, Federici, Massimo, Mauriello, Alessandro, Sangiorgi, Giuseppe Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9138496/
https://www.ncbi.nlm.nih.gov/pubmed/35625828
http://dx.doi.org/10.3390/biomedicines10051091
_version_ 1784714636755468288
author Bonanni, Michela
Rehak, Laura
Massaro, Gianluca
Benedetto, Daniela
Matteucci, Andrea
Russo, Giulio
Esperto, Francesco
Federici, Massimo
Mauriello, Alessandro
Sangiorgi, Giuseppe Massimo
author_facet Bonanni, Michela
Rehak, Laura
Massaro, Gianluca
Benedetto, Daniela
Matteucci, Andrea
Russo, Giulio
Esperto, Francesco
Federici, Massimo
Mauriello, Alessandro
Sangiorgi, Giuseppe Massimo
author_sort Bonanni, Michela
collection PubMed
description About 35% of patients affected by erectile dysfunction (ED) do not respond to oral phosphodiesterase-5 inhibitors (PDE5i) and more severe vasculogenic refractory ED affects diabetic patients. Innovative approaches, such as regenerative therapies, including stem cell therapy (SCT) and platelet-rich plasma (PRP), are currently under investigation. Recent data point out that the regenerative capacity of stem cells is strongly influenced by local immune responses, with macrophages playing a pivotal role in the injury response and as a coordinator of tissue regeneration, suggesting that control of the immune response could be an appealing approach in regenerative medicine. A new generation of autologous cell therapy based on immune cells instead of stem cells, which could change regenerative medicine for good, is discussed. Increasing safety and efficacy data are coming from clinical trials using peripheral blood mononuclear cells to treat no-option critical limb ischemia and diabetic foot. In this review, ongoing phase 1/phase 2 stem cell clinical trials are discussed. In addition, we examine the mechanism of action and rationale, as well as propose a new generation of regenerative therapies, evolving from typical stem cell or growth factor to immune cell-based medicine, based on autologous peripheral blood mononuclear cells (PBMNC) concentrates for the treatment of ED.
format Online
Article
Text
id pubmed-9138496
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91384962022-05-28 Autologous Immune Cell-Based Regenerative Therapies to Treat Vasculogenic Erectile Dysfunction: Is the Immuno-Centric Revolution Ready for the Prime Time? Bonanni, Michela Rehak, Laura Massaro, Gianluca Benedetto, Daniela Matteucci, Andrea Russo, Giulio Esperto, Francesco Federici, Massimo Mauriello, Alessandro Sangiorgi, Giuseppe Massimo Biomedicines Review About 35% of patients affected by erectile dysfunction (ED) do not respond to oral phosphodiesterase-5 inhibitors (PDE5i) and more severe vasculogenic refractory ED affects diabetic patients. Innovative approaches, such as regenerative therapies, including stem cell therapy (SCT) and platelet-rich plasma (PRP), are currently under investigation. Recent data point out that the regenerative capacity of stem cells is strongly influenced by local immune responses, with macrophages playing a pivotal role in the injury response and as a coordinator of tissue regeneration, suggesting that control of the immune response could be an appealing approach in regenerative medicine. A new generation of autologous cell therapy based on immune cells instead of stem cells, which could change regenerative medicine for good, is discussed. Increasing safety and efficacy data are coming from clinical trials using peripheral blood mononuclear cells to treat no-option critical limb ischemia and diabetic foot. In this review, ongoing phase 1/phase 2 stem cell clinical trials are discussed. In addition, we examine the mechanism of action and rationale, as well as propose a new generation of regenerative therapies, evolving from typical stem cell or growth factor to immune cell-based medicine, based on autologous peripheral blood mononuclear cells (PBMNC) concentrates for the treatment of ED. MDPI 2022-05-08 /pmc/articles/PMC9138496/ /pubmed/35625828 http://dx.doi.org/10.3390/biomedicines10051091 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Bonanni, Michela
Rehak, Laura
Massaro, Gianluca
Benedetto, Daniela
Matteucci, Andrea
Russo, Giulio
Esperto, Francesco
Federici, Massimo
Mauriello, Alessandro
Sangiorgi, Giuseppe Massimo
Autologous Immune Cell-Based Regenerative Therapies to Treat Vasculogenic Erectile Dysfunction: Is the Immuno-Centric Revolution Ready for the Prime Time?
title Autologous Immune Cell-Based Regenerative Therapies to Treat Vasculogenic Erectile Dysfunction: Is the Immuno-Centric Revolution Ready for the Prime Time?
title_full Autologous Immune Cell-Based Regenerative Therapies to Treat Vasculogenic Erectile Dysfunction: Is the Immuno-Centric Revolution Ready for the Prime Time?
title_fullStr Autologous Immune Cell-Based Regenerative Therapies to Treat Vasculogenic Erectile Dysfunction: Is the Immuno-Centric Revolution Ready for the Prime Time?
title_full_unstemmed Autologous Immune Cell-Based Regenerative Therapies to Treat Vasculogenic Erectile Dysfunction: Is the Immuno-Centric Revolution Ready for the Prime Time?
title_short Autologous Immune Cell-Based Regenerative Therapies to Treat Vasculogenic Erectile Dysfunction: Is the Immuno-Centric Revolution Ready for the Prime Time?
title_sort autologous immune cell-based regenerative therapies to treat vasculogenic erectile dysfunction: is the immuno-centric revolution ready for the prime time?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9138496/
https://www.ncbi.nlm.nih.gov/pubmed/35625828
http://dx.doi.org/10.3390/biomedicines10051091
work_keys_str_mv AT bonannimichela autologousimmunecellbasedregenerativetherapiestotreatvasculogenicerectiledysfunctionistheimmunocentricrevolutionreadyfortheprimetime
AT rehaklaura autologousimmunecellbasedregenerativetherapiestotreatvasculogenicerectiledysfunctionistheimmunocentricrevolutionreadyfortheprimetime
AT massarogianluca autologousimmunecellbasedregenerativetherapiestotreatvasculogenicerectiledysfunctionistheimmunocentricrevolutionreadyfortheprimetime
AT benedettodaniela autologousimmunecellbasedregenerativetherapiestotreatvasculogenicerectiledysfunctionistheimmunocentricrevolutionreadyfortheprimetime
AT matteucciandrea autologousimmunecellbasedregenerativetherapiestotreatvasculogenicerectiledysfunctionistheimmunocentricrevolutionreadyfortheprimetime
AT russogiulio autologousimmunecellbasedregenerativetherapiestotreatvasculogenicerectiledysfunctionistheimmunocentricrevolutionreadyfortheprimetime
AT espertofrancesco autologousimmunecellbasedregenerativetherapiestotreatvasculogenicerectiledysfunctionistheimmunocentricrevolutionreadyfortheprimetime
AT federicimassimo autologousimmunecellbasedregenerativetherapiestotreatvasculogenicerectiledysfunctionistheimmunocentricrevolutionreadyfortheprimetime
AT maurielloalessandro autologousimmunecellbasedregenerativetherapiestotreatvasculogenicerectiledysfunctionistheimmunocentricrevolutionreadyfortheprimetime
AT sangiorgigiuseppemassimo autologousimmunecellbasedregenerativetherapiestotreatvasculogenicerectiledysfunctionistheimmunocentricrevolutionreadyfortheprimetime